Document is current
Any future updates will be listed below
-
Authors
Qian, Ciying
Chen, Jie
Yang, Yurou
Lu, Yihan
Ren, Tianyu
Jiang, Yanan
Huang, Yang
Chi, Xin
Zhang, Shuyue
Zhang, Chengzong
Li, Kewei
Shen, Jingjia
Zhang, Sibo
Wang, Daning
Zhou, Lizhi
Li, Tingting
Zheng, Qingbing
Yu, Hai
Gu, Ying
Xia, Ningshao
Li, Shaowei
-
Funding
Funding for this research was provided by:
Natural Science Foundation of Xiamen Municipality (3502Z20227165)
National Natural Science Foundation of China (82171821)
National Natural Science Foundation of China (82271873)
Xiamen Industry-Academia-Research Project (2022CXY0107)
Fundamental Research Funds for the Central Universities (20720220006)
Fundamental Research Funds for the Central Universities (20720220004)
National Key Research and Development Program of China (2021YFC2301404)
- License Information
-
More Information
Article History
Received: 24 June 2024
Accepted: 20 December 2024
First Online: 20 January 2025
Declarations
:
: The experimental protocols were approved by the Xiamen University Laboratory Animal Management Ethics Committee. All manipulations were strictly conducted in compliance with animal ethics guidelines and approved protocols.
: There are two patents related to this article. Patent 1, titled "Mutant of L1 Protein of Human Papillomavirus Type 66," has been granted in the United States (Patent number: US11464846B2) and Japan (Patent number: 7337352), and has been filed in China with application numbers 201810563504.2 (priority) and 201910481217.1. Patent 2, titled "Mutant of L1 Protein of Human Papillomavirus Type 56," has been filed in China with application numbers 201810566209.2 (priority) and 201910481669.X.
